Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Glaxosmithkline Corporate Intellectual Property _ Uw2220 patentsThe following is a sampling of recent Glaxosmithkline Corporate Intellectual Property _ Uw2220 patent applications (USPTO Patent Application #, Patent Title) sorted by month.
July 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090176746 - Thrombopoietin mimetics
20090170066 - Methods and materials therefor
June 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090156597 - Novel compounds
20090148437 - Polypeptides, antibody variable domains & antagonists
20090143372 - Chemical compounds
20090143453 - Methods for treating degenerative diseases/injuries
May 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090130126 - Dna expression vectors
20090123496 - Purification of hbv antigens for use in vaccines
20090118280 - Compounds which potentiate ampa receptor and uses thereof in medicine
April 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090104229 - Novel use
20090104229 - Novel use
20090104229 - Novel use
20090105478 - Novel compounds
20090105478 - Novel compounds
20090105478 - Novel compounds
20090093478 - N-aroyl cyclic amines
March 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090082377 - Matrix metalloproteinase inhibitors
20090082390 - Piperidine compounds for use as orexin receptor antagonist
20090076274 - Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
February 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090053214 - Humanised anti-mag antibody or functional fragment thereof
20090053291 - Fusion proteins comprising hiv-1 tat and/or nef proteins
20090048318 - Methods for treating degenerative diseases/injuries
20090048442 - Novel compounds
20090048444 - Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
January 2009 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20090029986 - N-aroyl cyclic amines
20090022670 - Novel compounds
20090017020 - Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
20090018131 - Quinazoline derivatives as p13 kinase inhibitors
20090012073 - N-aroyl cyclic amines
20090012099 - Novel compounds
20090012122 - N-aroyl cyclic amine derivatives as orexin receptor antagonists
20090005401 - Novel compounds
October 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080260781 - Proteosome influenza vaccine
20080262069 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
20080255115 - Thiazolidinedione derivatives as pi3 kinase inhibitors
September 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080227858 - Inhibitors of matrix metalloproteinase
20080221110 - Compounds
20080213212 - Sialoadhesin factor-2 antibodies
20080214640 - Thrombopoietin mimetics
August 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080206189 - Method of treating cancer by administering conjugates comprising human il-18 and substitution mutants thereof
20080199494 - Vaccine
20080194648 - Compounds which potentiate glutamate receptor and uses thereof in medicine
20080188469 - Vaccination
July 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080181914 - Novel vaccine composition
20080182852 - Anthranilamide inhibitors of aurora kinase
20080176245 - Detection of viable agents
June 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080152671 - Novel vaccination
20080131464 - Vaccines
May 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080118527 - Novel composition
20080114010 - Novel substituted imidazole compounds
20080114049 - Chemical compounds
20080108615 - Imidazole-2-carboxamide derivatives as raf kinase inhibitors
20080102085 - Vaccine comprising gp120 and nef and/or tat for the immunization against hiv
20080102112 - Chlamydia vaccines
April 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080095854 - Dna dosage forms
20080096951 - Carvedilol monocitrate monohydrate
20080089902 - Fusion proteins comprising hiv-1 tat and/or nef proteins
20080089929 - Fusion proteins comprising hiv-1 tat and/or nef proteins
20080090787 - Thrombopoietin mimetics
20080090853 - Bicyclic heteroaromatic compounds
20080090881 - Treatment of diabetes with thiazolidinedione and metformin
20080090996 - Thrombopoietin mimetics
20080081050 - Vaccine against streptococcus pneumoniae
20080081808 - Azaindole inhibitors of aurora kinases
March 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080072992 - Novel process
20080076672 - Methods for identifying genes essential to the growth of an organism
20080076763 - Inhibitors of akt activity
20080070973 - Compounds having activity at the glyt1 transporter
20080063662 - Vaccine
20080057082 - Vaccine
20080058369 - Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
20080058378 - Compounds which have activity at m1 receptor and their uses in medicine.
20080058388 - Treatment of diabetes with thiazolidinedione and sulphonylurea
20080058398 - Compounds
February 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080044409 - Inflammatory mediator antagonists
January 2008 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20080025993 - Method for refolding neisserial nspa protein
20080019967 - Inflammatory mediator antagonists
20080021023 - Morpholinyl and pyrrolidinyl analogs
20080014195 - Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases
20080014266 - Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
20080004308 - Azaindole inhibitors of aurora kinases
December 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070298470 - Isolated dna comprising one or more genes specific for 5s clavam biosynthesis, vectors comprising such dna and streptomyces hosts capable of improved clavulanic acid production
20070281023 - Pharmaceutical composition for modified release insulin sensitiser
20070281977 - Novel heterocyclic compounds
November 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070274929 - Oral composition comprising chlorhexidine and maltitol or erythritol or a mixture thereof
20070275054 - Novel composition and use
20070275063 - Sustained release pharmaceutical compositions and methods of treatment using the same
20070275979 - Novel compounds
20070269451 - Nucleic acid vaccination
20070270456 - M3 muscarinic acetylcholine receptor antagonists
20070264258 - Sialoadhesin factor-2 antibodies
20070264283 - Vaccine
20070259882 - 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
20070259940 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
October 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070248679 - Vaccine
20070248997 - Method of using one-dimensional and multi-dimensional nuclear magnetic resonance to identify compounds that interact with target biomolecules
20070249664 - Muscarinic acetylcholine receptor antagonists
20070244123 - Heterocycle-carboxamide derivatives as raf kinase inhibitors
20070244150 - Muscarinic acetylcholine receptor antagonists
20070237788 - Non-live trivalent influenza vaccine for one-dose intradermal delivery
20070238151 - Novel compounds
20070238743 - 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
20070238757 - Novel treatment
20070232808 - Process for preparing heterocyclic derivatives
September 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070224198 - Antithrombotic agents
20070219232 - Chemical compounds
August 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070203200 - 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical
20070196394 - Immunogenic compositions comprising liver stage malarial antigens
20070190578 - Method of site specific labeling of proteins and uses therefor
20070191435 - Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
20070179144 - 5(z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
July 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070167423 - Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
20070167467 - 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
20070161083 - Codon optimized recombinant dermaphagoides allergens
20070161560 - Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain
20070151058 - Toothbrush
20070155762 - 5,6-trimethylenepyrimidin-4-one compounds
20070155792 - Peptide deformylase inhibitors
20070155810 - Peptide deformylase inhibitors
June 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070148995 - System for providing communication between the interior and the exterior of a compartment
20070149505 - Method of inhibiting adhesion formation
20070142451 - Carvedilol hydrobromide
20070135422 - Nitrogen-containing bicycle heterocycles for use as antibacterials
20070135433 - Imidazole derivatives as raf kinase inhibitors
20070129415 - Method of treating isolated systolic hypertension
May 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070122423 - Derp1 and proderp1 allergen derivatives
20070123549 - Pyrimidine compounds
20070112046 - 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
20070104784 - Compositions and methods of treatment comprising amoxicillin and potassium clavulante with xanthan
20070105860 - Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
April 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070087049 - Multi-component pharmaceutical dosage form
20070088064 - Pharmaceutical composition containing bicyclic type compounds
February 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070037859 - Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
20070031368 - Chemokine conjugates
January 2007 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20070020288 - Vaccine
20070021348 - Novel treatment
20070015769 - Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
20070004780 - Treatment of diabetes with thiazolidinedione and metformin
December 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060288510 - Toothbrush
20060292170 - Vaccine composition against malaria
20060292648 - Method of screening for inhibitors of osteopontin
20060280756 - Novel composition
November 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060269539 - Asp2
20060263852 - Asp2
20060263853 - Recombinant il4 antibodies useful in treatment of il4 mediated disorders
20060257418 - Vaccine
20060258687 - Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
20060251671 - Haemophilus influenza outer membrane protein and use thereof in vaccination
20060252799 - Benzo (f) insoindol derivatives and their use as ep4 receptor ligands
20060247279 - Thiazolidinedione derivative and its use as antidiabetic
October 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060240505 - Identification of targets of antimicrobial compounds
20060235026 - Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
20060235029 - Novel compounds
20060235030 - Novel compounds
20060223082 - Map
20060223819 - Quinoline derivatives as nk-3 antagonists
September 2006 - Glaxosmithkline Corporate Intellectual Property _ Uw2220 patents
20060204520 - Vaccine composition
20060205641 - Vanilrep4 polypeptides and vanilrep4 polynucleotides
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxosmithkline Corporate Intellectual Property _ Uw2220 in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Corporate Intellectual Property _ Uw2220 with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support
|
REGISTER now for FREE 
